Skip to main content

Table 4 Risks of death and hospitalisations

From: Clinical effects, cardiovascular and renal outcomes associated with rapid-acting insulin analogs among individuals with type 2 diabetes: a nation-wide observational cohort study

Event

Aspart vs lispro

Glulisine vs lispro

Glulisine vs aspart

Total Mortality

1.23 [0.98, 1.53]

0.65 [0.41, 1.53]

0.53 [0.35, 0.8]*

CHD

0.96 [0.82, 1.12]

1.03 [0.79, 1.36]

1.08 [0.85, 1.35]

Fatal CHD

1.17 [0.79, 1.74]

1.04 [0.50, 2.16]

0.89 [0.47, 1.67]

CVD

0.95 [0.82, 1.09]

1.03 [0.80, 1.31]

1.08 [0.88, 1.33]

Fatal CVD

1.15 [0.80, 1.66]

0.88 [0.44, 1.78]

0.77 [0.41, 1.42]

Stroke

0.94 [0.67, 1.34]

0.33 [0.16, 0.66]*

0.34 [0.18, 0.65]*

Heart Failure

1.00 [0.82, 1.23]

0.76 [0.50, 1.13]

0.75 [0.53, 1.08]

Kidney Failure

0.88 [0.68, 1.13]

0.71 [0.42, 1.20]

0.81 [0.50, 1.30]

Hypoglycaemia

1.42 [0.83, 2.44]

1.30 [0.55, 3.10]

0.92 [0.45, 1.85]

Hyperglycaemia

1.97 [1.01, 3.85]*

1.88 [0.66, 5.33]

0.96 [0.42, 2.18]

  1. Weighted Cox proportional hazards analysis. Estimated hazard ratios with 95% confidence intervals. * p-value <0.05